- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05620836
Une étude pour évaluer l'efficacité et l'innocuité du povorcitinib (INCB054707) chez des participants atteints d'hidrosadénite suppurée (HS) modérée à sévère (STOP-HS2)
Une étude de phase 3, en double aveugle, randomisée, contrôlée par placebo, d'efficacité et d'innocuité du povorcitinib (INCB054707) chez des participants atteints d'hidrosadénite suppurée modérée à sévère
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne, 10117
- Investigative Site DE202
-
Bochum, Allemagne, 44791
- Investigative Site DE203
-
Dessau, Allemagne, 06847
- Investigative Site DE201
-
Erlangen, Allemagne, 91054
- Investigative Site DE207
-
Göttingen, Allemagne, 37075
- Investigative Site DE208
-
Heidelberg, Allemagne, 69120
- Investigative Site DE205
-
Kiel, Allemagne, 24105
- Investigative Site DE200
-
Lübeck, Allemagne, 23538
- Investigative Site DE204
-
Mainz, Allemagne, 55131
- Investigative Site DE206
-
-
MA
-
Frankfurt am Main, MA, Allemagne, 60590
- Investigative Site US225
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australie, 02217
- Investigative Site AU205
-
Kotara, New South Wales, Australie, 02289
- Investigative Site AU203
-
Liverpool, New South Wales, Australie, 02170
- Investigative Site AU200
-
-
Queensland
-
Benowa, Queensland, Australie, 04217
- Investigative Site AU202
-
Woolloongabba, Queensland, Australie, 04102
- Investigative Site AU206
-
Woolloongabba, Queensland, Australie, 04102
- Investigative Site AU207
-
-
Victoria
-
Carlton, Victoria, Australie, 03053
- Investigative Site AU201
-
Melbourne, Victoria, Australie, 03002
- Investigative Site AU204
-
-
-
-
-
Sofia, Bulgarie, 01407
- Investigative Site BG203
-
Sofia, Bulgarie, 01463
- Investigative Site BG202
-
Sofia, Bulgarie, 01510
- Investigative Site BG200
-
Sofia, Bulgarie, 01606
- Investigative Site BG204
-
Stara Zagora, Bulgarie, 06000
- Investigative Site BG201
-
-
-
-
-
St. John's, Canada, A1A 4Y3
- Investigative Site CA203
-
-
Alberta
-
Calgary, Alberta, Canada, T3E 0B2
- Investigative Site CA202
-
Edmonton, Alberta, Canada, T6G 1C3
- Investigative Site CA204
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 0C6
- Investigative Site CA200
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Investigative Site CA205
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 0C2
- Investigative Site CA207
-
Richmond Hill, Ontario, Canada, L4C 9M7
- Investigative Site CA208
-
-
Quebec
-
Saint-Jérôme, Quebec, Canada, J7Z 7E2
- Investigative Site CA206
-
-
-
-
-
Roskilde, Danemark, 04000
- Investigative Site DK201
-
Århus N, Danemark, 08200
- Investigative Site DK200
-
-
-
-
-
Alicante, Espagne, 03010
- Investigative Site ES203
-
Las Palmas de Gran Canaria, Espagne, 35019
- Investigative Site ES202
-
Madrid, Espagne, 28005
- Investigative Site ES204
-
Madrid, Espagne, 28007
- Investigative Site ES201
-
Madrid, Espagne, 28040
- Investigative Site ES205
-
Manises, Espagne, 46940
- Investigative Site ES200
-
-
-
-
-
Antony, France, 92160
- Investigative Site FR200
-
Dijon, France, 21000
- Investigative Site FR205
-
Lyon, France, 69003
- Investigative Site FR204
-
Nice, France, 06200
- Investigative Site FR203
-
Reims, France, 51100
- Investigative Site FR206
-
Rouen, France, 76031
- Investigative Site FR202
-
Toulon, France, 83000
- Investigative Site FR201
-
-
-
-
-
Ancona, Italie, 60126
- Investigative Site IT200
-
Brescia, Italie, 25124
- Investigative Site IT204
-
Catania, Italie, 95123
- Investigative Site IT207
-
Milan, Italie, 20122
- Investigative Site IT202
-
Naples, Italie, 80131
- Investigative Site IT203
-
Pisa, Italie, 56126
- Investigative Site IT206
-
Roma, Italie, 00168
- Investigative Site IT205
-
Rozzano, Italie, 20089
- Investigative Site IT201
-
-
-
-
-
Lublin, Pologne, 20573
- Investigative Site PL203
-
Rzeszów, Pologne, 35-055
- Investigative Site PL200
-
Warsaw, Pologne, 02-507
- Investigative Site PL201
-
Warsaw, Pologne, 02-962
- Investigative Site PL202
-
-
-
-
-
Birmingham, Royaume-Uni, B15 2GW
- Investigative Site GB202
-
Dudley, Royaume-Uni, DY1 2HQ
- Investigative Site GB200
-
Leeds, Royaume-Uni, LS1 3EX
- Investigative Site GB201
-
London, Royaume-Uni, SE1 7EH
- Investigative Site GB204
-
Salford, Royaume-Uni, M6 8HD
- Investigative Site GB203
-
-
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85255
- Investigative Site US240
-
Scottsdale, Arizona, États-Unis, 85259
- Investigative Site US237
-
-
Arkansas
-
Arkansas City, Arkansas, États-Unis, 72758
- Investigative Site US214
-
Fayetteville, Arkansas, États-Unis, 72703
- Investigative Site US242
-
-
California
-
Los Angeles, California, États-Unis, 90033
- Investigative Site US223
-
San Diego, California, États-Unis, 92103
- Investigative Site US226
-
San Francisco, California, États-Unis, 94118
- Investigative Site US222
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20060
- Investigative Site US233
-
-
Florida
-
Brandon, Florida, États-Unis, 33511
- Investigative Site US228
-
Margate, Florida, États-Unis, 33063
- Investigative Site US227
-
Miami, Florida, États-Unis, 33125
- Investigative Site US204
-
Miami, Florida, États-Unis, 33173
- Investigative Site US236
-
Ocala, Florida, États-Unis, 34470
- Investigative Site US200
-
Tampa, Florida, États-Unis, 33613
- Investigative Site US201
-
-
Illinois
-
West Dundee, Illinois, États-Unis, 60118
- Investigative Site US220
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46250
- Investigative Site US206
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Investigative Site US241
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40241
- Investigative Site US209
-
-
Louisiana
-
Metairie, Louisiana, États-Unis, 70006
- Investigative Site US207
-
New Orleans, Louisiana, États-Unis, 70115
- Investigative Site US229
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21224
- Investigative Site US224
-
-
Massachusetts
-
Beverly, Massachusetts, États-Unis, 01915
- Investigative Site US208
-
Quincy, Massachusetts, États-Unis, 02169
- Investigative Site US221
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48084
- Investigative Site US213
-
Waterford, Michigan, États-Unis, 48328
- Investigative Site US217
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- Investigative Site US212
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68144
- Investigative Site US239
-
-
New Jersey
-
Hightstown, New Jersey, États-Unis, 08520
- Investigative Site US230
-
-
New York
-
New York, New York, États-Unis, 10003
- Investigative Site US202
-
Rochester, New York, États-Unis, 14642
- Investigative Site US210
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27516
- Investigative Site US205
-
-
Ohio
-
Bexley, Ohio, États-Unis, 43209
- Investigative Site US215
-
Columbus, Ohio, États-Unis, 43210
- Investigative Site US203
-
-
Tennessee
-
Murfreesboro, Tennessee, États-Unis, 37130
- Investigative Site US232
-
-
Texas
-
Arlington, Texas, États-Unis, 76011
- Investigative Site US235
-
Bellaire, Texas, États-Unis, 77401
- Investigative Site US218
-
Pflugerville, Texas, États-Unis, 78660
- Investigative Site US238
-
San Antonio, Texas, États-Unis, 78213
- Investigative Site US234
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male and female participants ≥ 18 years of age.
- Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.
- HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits.
- Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits.
- History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS)
- Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period.
- Willingness to avoid pregnancy or fathering children.
- Other inclusion criteria apply.
Exclusion Criteria:
- Draining tunnel count of > 20 at Screening or Baseline visits.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
- Evidence of infection with TB, HBV, HCV or HIV.
- History of failure to JAK inhibitor treatment of any inflammatory disease.
- Laboratory values outside of the protocol-defined ranges.
- Other exclusion criteria apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Povorcitinib Dose A
Participants will receive Povorcitinib Dose A for 54 weeks. |
Oral, Tablet
Autres noms:
|
|
Expérimental: Povorcitinib Dose B
Participants will receive Povorcitinib Dose B for 54 weeks. |
Oral, Tablet
Autres noms:
|
|
Comparateur placebo: Placebo
Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks. |
Oral, Tablet |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12
Délai: Baseline; Week 12
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Who Achieved HiSCR75 at Week 12
Délai: Baseline; Week 12
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 12
|
|
Percentage of Participants With Flare by Week 12
Délai: Baseline; Week 12
|
Participants who experienced at least 1 flare over 12 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; Week 12
|
|
Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3
Délai: Baseline; Week 12
|
Participants with a Skin Pain score of at least 3 at baseline and who experienced at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). |
Baseline; Week 12
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3
Délai: Baseline; Week 12
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 12, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). analyzed. |
Baseline; Week 12
|
|
Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12
Délai: Baseline; Week 12
|
Participants with a baseline FACIT-F score ≤48 and who experienced at least a 4-point increase in FACIT-F score at Week 12, relative to baseline, were assessed. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores for each item ranging from 0 (worst fatigue) to 4 (no fatigue). The total score is a sum of the 13 item scores and ranges from 0 (worst fatigue) to 52 (no fatigue). |
Baseline; Week 12
|
|
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in DLQI Score at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Abscess Count at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Abscess Count at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Délai: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
Délai: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib
Délai: Baseline; Week 24
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period
Délai: Baseline; Week 24
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib
Délai: Baseline; Week 24
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period
Délai: Baseline; Week 24
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib
Délai: Baseline; up to Week 24
|
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 24
|
|
Percentage of Participants With Flare by Week 24 During the Extension Period
Délai: Baseline; up to Week 24
|
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 24
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
Délai: Baseline; Week 24
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
Délai: Baseline; Week 24
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib
Délai: Baseline; Week 54
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period
Délai: Baseline; Week 54
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib
Délai: Baseline; Week 54
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period
Délai: Baseline; Week 54
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib
Délai: Baseline; up to Week 54
|
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 54
|
|
Percentage of Participants With Flare at Week 54 During the Extension Period
Délai: Baseline; up to Week 54
|
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 54
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
Délai: Baseline; Week 54
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
Délai: Baseline; Week 54
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved Maintenance of HiSCR50 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
Délai: up to 42 weeks (from end of Week 12 to end of Week 54)
|
Maintenance of response is defined as achieving HiSCR50 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
up to 42 weeks (from end of Week 12 to end of Week 54)
|
|
Percentage of Participants Who Achieved Maintenance of HiSCR75 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
Délai: up to 42 weeks (from end of Week 12 to end of Week 54)
|
Maintenance of response is defined as achieving HiSCR75 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
up to 42 weeks (from end of Week 12 to end of Week 54)
|
|
Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Délai: up to Week 16
|
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. |
up to Week 16
|
|
Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs
Délai: up to Week 16
|
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal. |
up to Week 16
|
|
Extension Period: Number of Participants With TEAEs
Délai: up to 46 weeks (from end of Week 12 to end of Week 58)
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. |
up to 46 weeks (from end of Week 12 to end of Week 58)
|
|
Extension Period: Number of Participants With ≥Grade 3 TEAEs
Délai: up to 46 weeks (from end of Week 12 to end of Week 58)
|
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal. |
up to 46 weeks (from end of Week 12 to end of Week 58)
|
|
Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs
Délai: up to Week 58
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. |
up to Week 58
|
|
Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs
Délai: up to Week 58
|
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal. |
up to Week 58
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- INCB 54707-302
- 2022-501753-36-00 (Identificateur de registre: EU CT Number)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Délai de partage IPD
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Critères d'accès au partage IPD
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .